CN104474201A - A kind of pharmaceutical composition for treating stomach disease and preparation method thereof - Google Patents
A kind of pharmaceutical composition for treating stomach disease and preparation method thereof Download PDFInfo
- Publication number
- CN104474201A CN104474201A CN201410717363.7A CN201410717363A CN104474201A CN 104474201 A CN104474201 A CN 104474201A CN 201410717363 A CN201410717363 A CN 201410717363A CN 104474201 A CN104474201 A CN 104474201A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- preparation
- add
- gastropathy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000018556 stomach disease Diseases 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 22
- 239000003814 drug Substances 0.000 claims abstract description 27
- 239000000843 powder Substances 0.000 claims abstract description 12
- 239000000284 extract Substances 0.000 claims abstract description 11
- 208000012895 Gastric disease Diseases 0.000 claims abstract 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 50
- 229930182470 glycoside Natural products 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 229940079593 drug Drugs 0.000 claims description 17
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims description 16
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims description 16
- 235000009685 Crataegus X maligna Nutrition 0.000 claims description 16
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims description 16
- 235000009486 Crataegus bullatus Nutrition 0.000 claims description 16
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims description 16
- 235000009682 Crataegus limnophila Nutrition 0.000 claims description 16
- 235000004423 Crataegus monogyna Nutrition 0.000 claims description 16
- 235000002313 Crataegus paludosa Nutrition 0.000 claims description 16
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims description 16
- 235000006533 astragalus Nutrition 0.000 claims description 16
- 239000000463 material Substances 0.000 claims description 16
- 241001061264 Astragalus Species 0.000 claims description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- -1 glycoside compound Chemical class 0.000 claims description 15
- 210000004233 talus Anatomy 0.000 claims description 15
- 238000000605 extraction Methods 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 10
- 235000009411 Rheum rhabarbarum Nutrition 0.000 claims description 10
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 10
- 239000003929 acidic solution Substances 0.000 claims description 10
- 239000012670 alkaline solution Substances 0.000 claims description 10
- 238000005406 washing Methods 0.000 claims description 10
- 238000010298 pulverizing process Methods 0.000 claims description 9
- 150000002338 glycosides Chemical class 0.000 claims description 7
- 241000092665 Atractylodes macrocephala Species 0.000 claims description 5
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 5
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 5
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 5
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 239000008367 deionised water Substances 0.000 claims description 5
- 229910021641 deionized water Inorganic materials 0.000 claims description 5
- 238000010828 elution Methods 0.000 claims description 5
- 239000012065 filter cake Substances 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 229940010454 licorice Drugs 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 239000012074 organic phase Substances 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 5
- 239000002244 precipitate Substances 0.000 claims description 5
- 239000011347 resin Substances 0.000 claims description 5
- 229920005989 resin Polymers 0.000 claims description 5
- 238000001179 sorption measurement Methods 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- 241000756943 Codonopsis Species 0.000 claims description 3
- 238000013375 chromatographic separation Methods 0.000 claims description 3
- 150000001408 amides Chemical class 0.000 claims description 2
- 239000008346 aqueous phase Substances 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- 240000000171 Crataegus monogyna Species 0.000 claims 2
- 244000299790 Rheum rhabarbarum Species 0.000 claims 2
- 240000004670 Glycyrrhiza echinata Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 10
- 210000002784 stomach Anatomy 0.000 abstract description 7
- 150000001875 compounds Chemical class 0.000 abstract description 6
- 239000012141 concentrate Substances 0.000 abstract description 5
- 230000006378 damage Effects 0.000 abstract description 4
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 235000013175 Crataegus laevigata Nutrition 0.000 abstract 1
- 241000657488 Crataegus rhipidophylla Species 0.000 abstract 1
- 235000017156 Crataegus rhipidophylla Nutrition 0.000 abstract 1
- 239000009636 Huang Qi Substances 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 239000000470 constituent Substances 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 235000012631 food intake Nutrition 0.000 description 24
- 230000037406 food intake Effects 0.000 description 22
- 241001092040 Crataegus Species 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 14
- 241000219061 Rheum Species 0.000 description 8
- 235000013305 food Nutrition 0.000 description 6
- 241000202807 Glycyrrhiza Species 0.000 description 4
- 238000000227 grinding Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000004952 Polyamide Substances 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 229920002647 polyamide Polymers 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 241000007126 Codonopsis pilosula Species 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- OVSQVDMCBVZWGM-SJWGPRHPSA-N Hyperin Natural products O[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-SJWGPRHPSA-N 0.000 description 2
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- QMNWISYXSJWHRY-YLNUDOOFSA-N astragaloside IV Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)[C@H]4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C[C@H]3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-YLNUDOOFSA-N 0.000 description 2
- QMNWISYXSJWHRY-BCBPIKMJSA-N astragaloside IV Natural products CC(C)(O)[C@@H]1CC[C@@](C)(O1)[C@H]2[C@@H](O)C[C@@]3(C)[C@@H]4C[C@H](O[C@@H]5O[C@H](CO)[C@H](O)[C@@H](O)[C@H]5O)[C@H]6C(C)(C)[C@H](CC[C@@]67C[C@@]47CC[C@]23C)O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O QMNWISYXSJWHRY-BCBPIKMJSA-N 0.000 description 2
- PFKIBRPYVNVMRU-UHFFFAOYSA-N cyclosieversioside F Natural products CC(C)(O)C1COC(C)(C1)C2C(O)CC3(C)C4CC(OC5OC(CO)C(O)C(O)C5O)C6C(C)(C)C(CCC67CC47CCC23C)OC8OCC(O)C(O)C8O PFKIBRPYVNVMRU-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- NQYPTLKGQJDGTI-FCVRJVSHSA-N hyperoside Natural products OC[C@H]1O[C@@H](OC2=C(Oc3cc(O)cc(O)c3[C@H]2O)c4ccc(O)c(O)c4)[C@H](O)[C@@H](O)[C@H]1O NQYPTLKGQJDGTI-FCVRJVSHSA-N 0.000 description 2
- 230000000622 irritating effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- OVSQVDMCBVZWGM-DTGCRPNFSA-N quercetin 3-O-beta-D-galactopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-DTGCRPNFSA-N 0.000 description 2
- BBFYUPYFXSSMNV-UHFFFAOYSA-N quercetin-7-o-galactoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-UHFFFAOYSA-N 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 1
- 241000045403 Astragalus propinquus Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010017817 Gastric polyps Diseases 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 235000020980 bad eating habits Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000030135 gastric motility Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 229940079905 intestinal adsorbents bismuth preparations Drugs 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
技术领域 technical field
本发明涉及药品的技术领域,特别是一种治疗胃病的药物组合物及其制备方法。 The invention relates to the technical field of medicines, in particular to a pharmaceutical composition for treating stomach diseases and a preparation method thereof.
背景技术 Background technique
胃病是一种常见的疾病,紧张的工作,学习,不良的饮食习惯(如酗酒、暴食、偏食以及饮食不规律、食用过多刺激性食品),药物刺激,细菌感染都可能使胃部产生应激性反应,使胃黏膜受损,而导致急性、慢性胃炎、胃溃疡、十二指肠溃疡、胃息肉、胃黏膜脱垂等一系列症状,胃病还存在有难以根治的特点,长此以往甚至会诱发胃部肿瘤、胃癌等重疾。 Stomach disease is a common disease. Stressful work, study, bad eating habits (such as alcoholism, overeating, partial eclipse, irregular diet, and eating too much irritating food), drug stimulation, and bacterial infection may cause stress in the stomach. The irritative reaction damages the gastric mucosa, leading to a series of symptoms such as acute and chronic gastritis, gastric ulcer, duodenal ulcer, gastric polyps, and gastric mucosal prolapse. Induce gastric cancer, gastric cancer and other serious diseases.
由于生活的紧张与工作的压力所致,不少胃病患者为求短时间可见疗效,而服用促胃动力药、含铝制剂、胃黏膜保护剂、铋剂等复方西药制剂,此类药物虽能作用快,能在短时间抑制胃病的发作,但难以治本,且这些药物不同程度的存在有副作用,被人体吸收后,会影响肝、肾、脾、脑、骨骼等器官组织造成不同程度的损伤;使用中药治疗胃病虽然副作用程度较小,但存在见效慢,服用不方便的特点。 Due to the tension of life and the pressure of work, many patients with stomach problems take compound western medicine preparations such as gastric motility drugs, aluminum-containing preparations, gastric mucosal protective agents, bismuth preparations, etc., in order to see curative effect in a short time. It acts quickly and can suppress the onset of stomach problems in a short time, but it is difficult to cure the root cause, and these drugs have side effects in varying degrees. After being absorbed by the human body, they will affect the liver, kidney, spleen, brain, bones and other organs and tissues to cause varying degrees of damage. ; Although the degree of side effects of using traditional Chinese medicine to treat stomach disease is small, there are slow effects and inconvenient characteristics to take.
发明内容 Contents of the invention
本发明的目的在于:提供一种治疗胃病的药物组合物及其制备方法,通过提取出其针对胃病的黄芪、刺五加、山楂的有效成分,并进行浓缩提取,之后加入养胃护胃的药物粉末以增强其治疗效果,可达到与治疗胃病的复方西药制剂同等效果,并避免服用西药对人体造成过强的毒副作用,让患者能尽早摆脱胃病的折磨,以及免受毒副作用的二次伤害。 The object of the present invention is to provide a pharmaceutical composition for treating stomach diseases and its preparation method. By extracting the active ingredients of Astragalus, Acanthopanax, and Hawthorn for stomach diseases, and carrying out concentrated extraction, then adding stomach-nourishing and stomach-protecting ingredients The drug powder can enhance its therapeutic effect, which can achieve the same effect as the compound western medicine preparation for treating stomach diseases, and avoid excessive toxic and side effects on the human body caused by taking western medicine, so that patients can get rid of the torment of stomach diseases as soon as possible, and avoid the secondary effects of toxic and side effects harm.
为解决上述技术问题,本发明采取以下技术方案: In order to solve the problems of the technologies described above, the present invention takes the following technical solutions:
一种治疗胃病的药物组合物及其制备方法,由以下物料按重量分数比制成: A pharmaceutical composition for treating stomach diseases and a preparation method thereof, which are made of the following materials in proportion by weight:
苷类化合物20-25份、山药10-12份、徐长卿5-7份、神曲5-7份、大黄4-6份、党参3-5份、白术3-5份、甘草3-5份、大黄4-6份。 20-25 parts of glycosides, 10-12 parts of yam, 5-7 parts of Xu Changqing, 5-7 parts of Divine Comedy, 4-6 parts of rhubarb, 3-5 parts of Codonopsis, 3-5 parts of Atractylodes macrocephala, 3-5 parts of licorice, 4-6 parts of rhubarb.
所述的苷类化合物由黄芪、刺五加、山楂按20-25:30-40:10-15的重量比,提取后制得。 The glycoside compound is prepared by extracting Astragalus, Acanthopanax and Hawthorn according to the weight ratio of 20-25:30-40:10-15.
一种治疗胃病的药物组合物及其制备方法,包括以下步骤: A pharmaceutical composition for treating stomach diseases and a preparation method thereof, comprising the following steps:
步骤1:取黄芪、刺五加、山楂洗净,干燥,粉碎处理后并混合,以8-10倍量,浓度为50%-70%的含水乙醇回流提取2-3次,每次3-4小时,将提取液过滤,合并滤液减压浓缩至无乙醇气味,再经过大孔吸附树脂,以5倍柱体积的50%-70%的含水乙醇梯度洗脱,后再次进行减压浓缩至无乙醇气味,之后加入碱性溶液,调节pH至9-10,在35-40℃下反应8-10小时后加入酸性溶液调节pH至6.8-7.2,加入正丁醇萃取,收集有机相经聚酰胺柱进行层析分离,再使用50%-70%的含水乙醇进行梯度洗脱,进行减压浓缩至相对密度为1.2,再加入乙酸乙酯萃取,收集水相并浓缩至相对密度为1.3,静置后将沉淀完全过滤,滤饼用水洗涤后,在将其用甲醇进行重结晶,得到粉末为以上成分的苷类化合物。 Step 1: Take Astragalus, Acanthopanax, and Hawthorn, wash, dry, crush and mix, and extract 2-3 times with 8-10 times the amount of aqueous ethanol with a concentration of 50%-70%, 3-3 times each time After 4 hours, the extract was filtered, and the combined filtrate was concentrated under reduced pressure until there was no ethanol smell, then passed through a macroporous adsorption resin, and eluted with a gradient of 50%-70% aqueous ethanol for 5 times the column volume, and then concentrated under reduced pressure again to No ethanol smell, then add alkaline solution, adjust pH to 9-10, react at 35-40°C for 8-10 hours, add acidic solution to adjust pH to 6.8-7.2, add n-butanol for extraction, collect organic phase and polymerize The amide column was subjected to chromatographic separation, followed by gradient elution with 50%-70% aqueous ethanol, concentrated under reduced pressure to a relative density of 1.2, then added ethyl acetate for extraction, collected the aqueous phase and concentrated it to a relative density of 1.3, After standing still, the precipitate is completely filtered, and the filter cake is washed with water, and then recrystallized with methanol to obtain the glycoside compound with the above components as powder.
本步骤所述的粉碎是将黄芪、刺五加、山楂粉碎并过20目筛。 The pulverization described in this step is to pulverize Astragalus, Acanthopanax, and Hawthorn and pass through a 20-mesh sieve.
本步骤所述的碱性溶液为质量浓度为2%的氢氧化钠或氢氧化钾溶液。 The alkaline solution described in this step is a sodium hydroxide or potassium hydroxide solution with a mass concentration of 2%.
本步骤所述的酸性溶液时质量浓度为4的稀硫酸或稀盐酸。 The acidic solution described in this step is dilute sulfuric acid or dilute hydrochloric acid with a mass concentration of 4.
本步骤所述的用水洗涤是使用去离子水进行洗涤。 The washing with water described in this step is to use deionized water for washing.
步骤2:将余下的物料进行粉碎,与苷类化合物粉末混合均匀,得到所述的治疗胃病的药物组合物。 Step 2: Grinding the remaining materials and mixing them evenly with glycoside compound powder to obtain the pharmaceutical composition for treating stomach diseases.
本步骤所述的粉碎是将余下物料粉碎过200目筛。 The pulverization described in this step is to pulverize the remaining materials through a 200-mesh sieve.
优选的,本领域技术人员可以根据所学知识,在本发明中加入药学上可接受的辅料或辅助性成分制备成的药学上常用的药物,如片剂、胶囊、冲剂、口服液、滴丸等药物。 Preferably, those skilled in the art can add pharmaceutically acceptable adjuvants or auxiliary components to the present invention to prepare pharmaceutically commonly used drugs, such as tablets, capsules, granules, oral liquids, and dripping pills, according to what they have learned. and other drugs.
本发明的有益之处在于,将黄芪中的黄芪甲苷与刺五加、山楂中的金丝桃苷一同进行联合粗提,在尽量将黄芪甲苷、金丝桃苷提取出来的同时,联合粗提可减少不必要的操作工序;同时将其余对胃病有效的、养胃的药物粉碎与苷类化合物混合,可提高苷类化合物治疗胃病、养护胃部的功效。 The benefit of the present invention is that astragaloside IV in Astragalus membranaceus is combined with hyperoside in Acanthopanax and hawthorn, and while extracting astragaloside IV and hyperoside as much as possible, combined Rough extraction can reduce unnecessary operation procedures; at the same time, the rest of the drugs that are effective for stomach diseases and nourish the stomach are crushed and mixed with glycosides, which can improve the efficacy of glycosides in treating stomach diseases and maintaining the stomach.
具体实施方式 Detailed ways
本发明公开了一种治疗胃病的药物组合物及其制备方法,本领域的技术人员可以借鉴本文内容,适当改造工艺参数实现本品的制作。特别需要指出的是,所有类似的替换和改动对本领域技术人员来说是显而易见的,他们都被视为包括在本发明。本发明所述的治疗胃病的药物组合物及其制备方法已经经过了较佳的实施例进行了描述,相关人员明显能在不脱离本发明内容、精神和范围内对本文所述的方法和应用进行改动或适当变更与组合,来实现和应用本发明技术。 The invention discloses a pharmaceutical composition for treating stomach diseases and a preparation method thereof. Those skilled in the art can refer to the content of this article and appropriately modify process parameters to realize the preparation of the product. In particular, it should be pointed out that all similar replacements and modifications that are obvious to those skilled in the art are deemed to be included in the present invention. The pharmaceutical composition for treating stomach disease of the present invention and its preparation method have been described in preferred embodiments, and relevant personnel can obviously understand the method and application described herein without departing from the content, spirit and scope of the present invention. Make changes or appropriate changes and combinations to realize and apply the technology of the present invention.
如无特别说明,在具体实施方式中涉及的试验材料均可从市场自由购得。 Unless otherwise specified, the test materials involved in the specific embodiments can be purchased freely from the market.
以下结合实施例对本发明进行具体说明: The present invention is specifically described below in conjunction with embodiment:
实施例1 Example 1
一种治疗胃病的药物组合物,由以下物料按重量分数比制成: A pharmaceutical composition for treating stomach diseases, made of the following materials in proportion by weight:
苷类化合物20份、山药10份、徐长卿5份、神曲5份、大黄4份、党参3份、白术3份、甘草3份、大黄4份。 20 parts of glycosides, 10 parts of yam, 5 parts of Xu Changqing, 5 parts of Divine Comedy, 4 parts of rhubarb, 3 parts of Codonopsis pilosula, 3 parts of Atractylodes macrocephala, 3 parts of licorice, and 4 parts of rhubarb.
所述的苷类化合物由黄芪、刺五加、山楂按20:30:10的重量比,提取后制得。 The glycoside compound is prepared by extracting Astragalus, Acanthopanax and Hawthorn in a weight ratio of 20:30:10.
一种治疗胃病的药物组合物及其制备方法,包括以下步骤: A pharmaceutical composition for treating stomach diseases and a preparation method thereof, comprising the following steps:
步骤1:取黄芪、刺五加、山楂洗净,干燥,粉碎处理后并混合,以8倍量,浓度为50%的含水乙醇回流提取2次,每次3小时,将提取液过滤,合并滤液减压浓缩至无乙醇气味,再经过大孔吸附树脂,以5倍柱体积的50%的含水乙醇梯度洗脱,后再次进行减压浓缩至无乙醇气味,之后加入碱性溶液,调节pH至9,在35℃下反应8小时后加入酸性溶液调节pH至6.8,加入正丁醇萃取,收集有机相经聚酰胺柱进行层析分离,再使用50%的含水乙醇进行梯度洗脱,进行减压浓缩至相对密度为1.2,再加入乙酸乙酯萃取,收集水相并浓缩至相对密度为1.3,静置后将沉淀完全过滤,滤饼用水洗涤后,在将其用甲醇进行重结晶,得到粉末为以上成分的苷类化合物。 Step 1: Take Astragalus, Acanthopanax, and Hawthorn, wash, dry, crush and mix, and extract twice with 8 times the amount of 50% aqueous ethanol, 3 hours each time, filter the extract, and combine The filtrate was concentrated under reduced pressure until there was no ethanol smell, then passed through a macroporous adsorption resin, and eluted with a gradient of 50% aqueous ethanol for 5 times the column volume, and then concentrated under reduced pressure again until there was no ethanol smell, and then an alkaline solution was added to adjust the pH to 9, after reacting at 35°C for 8 hours, adding an acidic solution to adjust the pH to 6.8, adding n-butanol for extraction, collecting the organic phase through a polyamide column for chromatographic separation, and then using 50% aqueous ethanol for gradient elution. Concentrate under reduced pressure to a relative density of 1.2, then add ethyl acetate for extraction, collect the water phase and concentrate to a relative density of 1.3, after standing still, filter the precipitate completely, wash the filter cake with water, and recrystallize it with methanol, The obtained powder is the glycoside compound of the above composition.
本步骤所述的粉碎是将黄芪、刺五加、山楂粉碎并过20目筛。 The pulverization described in this step is to pulverize Astragalus, Acanthopanax, and Hawthorn and pass through a 20-mesh sieve.
本步骤所述的碱性溶液为质量浓度为2%的氢氧化钠或氢氧化钾溶液。 The alkaline solution described in this step is a sodium hydroxide or potassium hydroxide solution with a mass concentration of 2%.
本步骤所述的酸性溶液时质量浓度为4的稀硫酸或稀盐酸。 The acidic solution described in this step is dilute sulfuric acid or dilute hydrochloric acid with a mass concentration of 4.
本步骤所述的用水洗涤是使用去离子水进行洗涤。 The washing with water described in this step is to use deionized water for washing.
步骤2:将余下的物料进行粉碎,与苷类化合物粉末混合均匀,得到所述的治疗胃病的药物组合物。 Step 2: Grinding the remaining materials and mixing them evenly with glycoside compound powder to obtain the pharmaceutical composition for treating stomach diseases.
本步骤所述的粉碎是将余下物料粉碎过200目筛。 The pulverization described in this step is to pulverize the remaining materials through a 200-mesh sieve.
优选的,本领域技术人员可以根据所学知识,在本发明中加入药学上可接受的辅料或辅助性成分制备成的药学上常用的药物,如片剂、胶囊、冲剂、口服液、滴丸等药物。 Preferably, those skilled in the art can add pharmaceutically acceptable adjuvants or auxiliary components to the present invention to prepare pharmaceutically commonly used drugs, such as tablets, capsules, granules, oral liquids, and dripping pills, according to what they have learned. and other drugs.
实施例2 Example 2
一种治疗胃病的药物组合物,由以下物料按重量分数比制成: A pharmaceutical composition for treating stomach diseases, made of the following materials in proportion by weight:
苷类化合物23份、山药11份、徐长卿6份、神曲6份、大黄5份、党参4份、白术4份、甘草4份、大黄5份。 23 parts of glycosides, 11 parts of yam, 6 parts of Xu Changqing, 6 parts of Shenqu, 5 parts of rhubarb, 4 parts of Codonopsis pilosula, 4 parts of Atractylodes macrocephala, 4 parts of licorice, and 5 parts of rhubarb.
所述的苷类化合物由黄芪、刺五加、山楂按23:35:13的重量比,提取后制得。 The glycoside compound is prepared by extracting Astragalus, Acanthopanax and Hawthorn according to the weight ratio of 23:35:13.
一种治疗胃病的药物组合物及其制备方法,包括以下步骤: A pharmaceutical composition for treating stomach diseases and a preparation method thereof, comprising the following steps:
步骤1:取黄芪、刺五加、山楂洗净,干燥,粉碎处理后并混合,以9倍量,浓度为60%的含水乙醇回流提取3次,每次3.5小时,将提取液过滤,合并滤液减压浓缩至无乙醇气味,再经过大孔吸附树脂,以5倍柱体积的60%的含水乙醇梯度洗脱,后再次进行减压浓缩至无乙醇气味,之后加入碱性溶液,调节pH至9.5,在38℃下反应9小时后加入酸性溶液调节pH至7,加入正丁醇萃取,收集有机相经聚酰胺柱进行层析分离,再使用60%的含水乙醇进行梯度洗脱,进行减压浓缩至相对密度为1.2,再加入乙酸乙酯萃取,收集水相并浓缩至相对密度为1.3,静置后将沉淀完全过滤,滤饼用水洗涤后,在将其用甲醇进行重结晶,得到粉末为以上成分的苷类化合物。 Step 1: Take Astragalus, Acanthopanax, and Hawthorn, wash, dry, crush and mix, use 9 times the amount of water-containing ethanol with a concentration of 60% to reflux extract 3 times, each time for 3.5 hours, filter the extract, and combine The filtrate was concentrated under reduced pressure until there was no ethanol smell, then passed through a macroporous adsorption resin, and eluted with a gradient of 60% aqueous ethanol for 5 times the column volume, and then concentrated under reduced pressure again until there was no ethanol smell, and then an alkaline solution was added to adjust the pH to 9.5, react at 38°C for 9 hours, add an acidic solution to adjust the pH to 7, add n-butanol for extraction, collect the organic phase and carry out chromatography on a polyamide column, and then use 60% aqueous ethanol for gradient elution. Concentrate under reduced pressure to a relative density of 1.2, then add ethyl acetate for extraction, collect the water phase and concentrate to a relative density of 1.3, after standing still, filter the precipitate completely, wash the filter cake with water, and recrystallize it with methanol, The obtained powder is the glycoside compound of the above composition.
本步骤所述的粉碎是将黄芪、刺五加、山楂粉碎并过20目筛。 The pulverization described in this step is to pulverize Astragalus, Acanthopanax, and Hawthorn and pass through a 20-mesh sieve.
本步骤所述的碱性溶液为质量浓度为2%的氢氧化钠或氢氧化钾溶液。 The alkaline solution described in this step is a sodium hydroxide or potassium hydroxide solution with a mass concentration of 2%.
本步骤所述的酸性溶液时质量浓度为4的稀硫酸或稀盐酸。 The acidic solution described in this step is dilute sulfuric acid or dilute hydrochloric acid with a mass concentration of 4.
本步骤所述的用水洗涤是使用去离子水进行洗涤。 The washing with water described in this step is to use deionized water for washing.
步骤2:将余下的物料进行粉碎,与苷类化合物粉末混合均匀,得到所述的治疗胃病的药物组合物。 Step 2: Grinding the remaining materials and mixing them evenly with glycoside compound powder to obtain the pharmaceutical composition for treating stomach diseases.
本步骤所述的粉碎是将余下物料粉碎过200目筛。 The pulverization described in this step is to pulverize the remaining materials through a 200-mesh sieve.
优选的,本领域技术人员可以根据所学知识,在本发明中加入药学上可接受的辅料或辅助性成分制备成的药学上常用的药物,如片剂、胶囊、冲剂、口服液、滴丸等药物。 Preferably, those skilled in the art can add pharmaceutically acceptable adjuvants or auxiliary components to the present invention to prepare pharmaceutically commonly used drugs, such as tablets, capsules, granules, oral liquids, and dripping pills, according to what they have learned. and other drugs.
实施例3 Example 3
一种治疗胃病的药物组合物及其制备方法,由以下物料按重量分数比制成: A pharmaceutical composition for treating stomach diseases and a preparation method thereof, which are made of the following materials in proportion by weight:
苷类化合物25份、山药12份、徐长卿7份、神曲7份、大黄6份、党参5份、白术5份、甘草5份、大黄6份。 25 parts of glycosides, 12 parts of yam, 7 parts of Xu Changqing, 7 parts of Divine Comedy, 6 parts of rhubarb, 5 parts of Codonopsis, 5 parts of Atractylodes macrocephala, 5 parts of licorice, and 6 parts of rhubarb.
所述的苷类化合物由黄芪、刺五加、山楂按25:40:15的重量比,提取后制得。 The glycoside compound is prepared by extracting Astragalus, Acanthopanax and Hawthorn in a weight ratio of 25:40:15.
一种治疗胃病的药物组合物及其制备方法,包括以下步骤: A pharmaceutical composition for treating stomach diseases and a preparation method thereof, comprising the following steps:
步骤1:取黄芪、刺五加、山楂洗净,干燥,粉碎处理后并混合,以10倍量,浓度为70%的含水乙醇回流提取3次,每次4小时,将提取液过滤,合并滤液减压浓缩至无乙醇气味,再经过大孔吸附树脂,以5倍柱体积的70%的含水乙醇梯度洗脱,后再次进行减压浓缩至无乙醇气味,之后加入碱性溶液,调节pH至9-10,在40℃下反应10小时后加入酸性溶液调节pH至7.2,加入正丁醇萃取,收集有机相经聚酰胺柱进行层析分离,再使用70%的含水乙醇进行梯度洗脱,进行减压浓缩至相对密度为1.2,再加入乙酸乙酯萃取,收集水相并浓缩至相对密度为1.3,静置后将沉淀完全过滤,滤饼用水洗涤后,在将其用甲醇进行重结晶,得到粉末为以上成分的苷类化合物。 Step 1: Take Astragalus, Acanthopanax, and Hawthorn, wash, dry, crush and mix, and extract 3 times with 10 times the amount of 70% aqueous ethanol, 4 hours each time, filter the extract, and combine The filtrate was concentrated under reduced pressure until there was no ethanol smell, then passed through a macroporous adsorption resin, and eluted with a gradient of 70% aqueous ethanol for 5 times the column volume, and then concentrated under reduced pressure again until there was no ethanol smell, and then an alkaline solution was added to adjust the pH To 9-10, react at 40°C for 10 hours, add acidic solution to adjust the pH to 7.2, add n-butanol for extraction, collect the organic phase and separate it by polyamide column chromatography, and then use 70% aqueous ethanol for gradient elution , concentrated under reduced pressure to a relative density of 1.2, then added ethyl acetate for extraction, collected the water phase and concentrated to a relative density of 1.3, and filtered the precipitate completely after standing, washed the filter cake with water, and then re-introduced it with methanol Crystallization, the powder is the glycoside compound of the above composition.
本步骤所述的粉碎是将黄芪、刺五加、山楂粉碎并过20目筛。 The pulverization described in this step is to pulverize Astragalus, Acanthopanax, and Hawthorn and pass through a 20-mesh sieve.
本步骤所述的碱性溶液为质量浓度为2%的氢氧化钠或氢氧化钾溶液。 The alkaline solution described in this step is a sodium hydroxide or potassium hydroxide solution with a mass concentration of 2%.
本步骤所述的酸性溶液时质量浓度为4的稀硫酸或稀盐酸。 The acidic solution described in this step is dilute sulfuric acid or dilute hydrochloric acid with a mass concentration of 4.
本步骤所述的用水洗涤是使用去离子水进行洗涤。 The washing with water described in this step is to use deionized water for washing.
步骤2:将余下的物料进行粉碎,与苷类化合物粉末混合均匀,得到所述的治疗胃病的药物组合物。 Step 2: Grinding the remaining materials and mixing them evenly with glycoside compound powder to obtain the pharmaceutical composition for treating stomach diseases.
本步骤所述的粉碎是将余下物料粉碎过200目筛。 The pulverization described in this step is to pulverize the remaining materials through a 200-mesh sieve.
优选的,本领域技术人员可以根据所学知识,在本发明中加入药学上可接受的辅料或辅助性成分制备成的药学上常用的药物,如片剂、胶囊、冲剂、口服液、滴丸等药物。 Preferably, those skilled in the art can add pharmaceutically acceptable adjuvants or auxiliary components to the present invention to prepare pharmaceutically commonly used drugs, such as tablets, capsules, granules, oral liquids, and dripping pills, according to what they have learned. and other drugs.
测试例 test case
使用小鼠作为本测试例的测试动物,选择小鼠200只进行前期准备,将混有幽门螺杆菌的食物作为小鼠的日常食物,小鼠食用该食物12周后,其食量下降过半,选用其中的食量较为接近的小鼠100只,分为5组,分别将本产品各实施例以及两款市面上销售的复方西药胃药混入小鼠的食物中,进行对比测试,测试中每天在同一时间段喂养小鼠足量同等食物5回,每4小时一回,每天收集组别小鼠食用量,持续4周后对以小鼠食量对本产品进行初步的简单评测。 Using mice as the test animals of this test example, 200 mice were selected for preliminary preparation, and the food mixed with Helicobacter pylori was used as the daily food of the mice. After the mice ate the food for 12 weeks, their food intake dropped by more than half. Among them, 100 mice with relatively similar food intake were divided into 5 groups. Each embodiment of this product and two compound western medicine gastric medicines sold on the market were mixed into the food of the mice respectively, and a comparative test was carried out. During the time period, the mice were fed with the same amount of food for 5 times, once every 4 hours, and the food consumption of the mice in each group was collected every day. After 4 weeks, a preliminary simple evaluation of the product was carried out based on the food consumption of the mice.
测试例1 test case 1
小鼠在测试期第一周,食量逐渐增加,第二周中期开始食量恢复正常,第三周开始食量与前期准备前食量持平甚至有所增加,第四周保持第三周食量水平。 In the first week of the test period, the food intake of the mice gradually increased, and the food intake returned to normal in the middle of the second week, and the food intake in the third week was the same as that before the preparation or even increased, and the food intake in the fourth week remained at the level of the third week.
测试例2 test case 2
小鼠在测试期第一周,食量逐渐增加,第二周开始食量恢复正常,第二周周末开始食量与前期准备前食量持平甚至有所增加,直至第四周保持第二周周末食量水平。 During the first week of the test period, the food intake of the mice gradually increased, and the food intake returned to normal in the second week. The food intake at the weekend of the second week was the same as that before the previous preparation or even increased, and remained at the weekend food intake level of the second week until the fourth week.
测试例3 Test case 3
小鼠在测试期第一周,食量逐渐增加,第二周开始食量恢复正常,第二周周末开始食量与前期准备前食量持平甚至有所增加,直至第四周保持第二周周末食量水平。 During the first week of the test period, the food intake of the mice gradually increased, and the food intake returned to normal in the second week. The food intake at the weekend of the second week was the same as that before the previous preparation or even increased, and remained at the weekend food intake level of the second week until the fourth week.
复方西药对照组1 Compound western medicine control group 1
小鼠在测试期第一周,食量逐渐增加,第二周开始食量恢复正常,第三周开始食量与前期准备前食量持平甚至有所增加,第四周保持第三周食量水平。 In the first week of the test period, the food intake of the mice gradually increased, and the food intake returned to normal in the second week, and the food intake in the third week was the same as that before the preparation or even increased, and the food intake in the fourth week remained at the level of the third week.
复方西药对照组2 Compound western medicine control group 2
小鼠在测试期第一周,食量逐渐增加,第二周中期开始食量恢复正常,第二周周末食量与前期准备前食量持平甚至有所增加,直至第四周保持第二周周末食量水平。 In the first week of the test period, the food intake of the mice gradually increased, and the food intake returned to normal in the middle of the second week, and the food intake at the weekend of the second week was the same as that before the previous preparation, or even increased, and remained at the weekend food intake level of the second week until the fourth week.
以上所述,仅为本发明的具体实施方式,但本发明的保护范围并不局限于此, 任何熟悉本领域的技术人员在本发明所揭露的技术范围内,可不经过创造性劳动想到的变化或替换,都应涵盖在本发明的保护范围之内。因此,本发明的保护范围应该以权利要求书所限定的保护范围为准。 The above is only a specific embodiment of the present invention, but the scope of protection of the present invention is not limited thereto. Any person skilled in the art may make changes or modifications without creative work within the technical scope disclosed in the present invention. Replacement should be covered within the protection scope of the present invention. Therefore, the protection scope of the present invention should be determined by the protection scope defined in the claims.
Claims (3)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410717363.7A CN104474201A (en) | 2014-12-02 | 2014-12-02 | A kind of pharmaceutical composition for treating stomach disease and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410717363.7A CN104474201A (en) | 2014-12-02 | 2014-12-02 | A kind of pharmaceutical composition for treating stomach disease and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104474201A true CN104474201A (en) | 2015-04-01 |
Family
ID=52748902
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410717363.7A Pending CN104474201A (en) | 2014-12-02 | 2014-12-02 | A kind of pharmaceutical composition for treating stomach disease and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104474201A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101856412A (en) * | 2009-04-09 | 2010-10-13 | 刘君峰 | Chinese medicament for treating gastroptosis |
| CN102641454A (en) * | 2012-05-22 | 2012-08-22 | 江苏省中医药研究院 | Traditional Chinese medicine composition for treating chronic atrophic gastritis |
| CN102698175A (en) * | 2012-03-20 | 2012-10-03 | 章崇芝 | Traditional Chinese medicinal composition for treating gastroptosis |
-
2014
- 2014-12-02 CN CN201410717363.7A patent/CN104474201A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101856412A (en) * | 2009-04-09 | 2010-10-13 | 刘君峰 | Chinese medicament for treating gastroptosis |
| CN102698175A (en) * | 2012-03-20 | 2012-10-03 | 章崇芝 | Traditional Chinese medicinal composition for treating gastroptosis |
| CN102641454A (en) * | 2012-05-22 | 2012-08-22 | 江苏省中医药研究院 | Traditional Chinese medicine composition for treating chronic atrophic gastritis |
Non-Patent Citations (6)
| Title |
|---|
| 张长庆等: "慢性胃病中医三层次辨证用药探讨", 《四川中医》 * |
| 王来法: "《标本兼治看胃病——30年诊疗经验》", 30 July 2013 * |
| 赵余庆: "《中药及天然产物提取制备关键技术》", 31 January 2012 * |
| 郝中珍: "胃复汤治疗慢性萎缩性胃炎68例", 《河北中医》 * |
| 陈月波: "辨证治疗萎缩性胃炎", 《中医杂志》 * |
| 龚超: "辨证治疗萎缩性胃炎", 《湖北中医杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100515484C (en) | Medications containing ilaprazole | |
| CN101810636A (en) | Application of Chinese yam polysaccharide in preparation of medicine for treating obesity | |
| CN104510853B (en) | A kind of Chinese medicinal effective-part composition for the treatment of dysmenorrhes and uses thereof | |
| CN104474021A (en) | Traditional Chinese medicine composition for treatment of exterior heat and preparation method thereof | |
| CN101396528A (en) | Traditional Chinese medicine composite preparation for treating wind-heat cold | |
| CN104666927B (en) | A kind of Chinese medicine composition and its adjust immune function of human body and/or antitumor application thereof | |
| CN101934062A (en) | A kind of traditional Chinese medicine composition for treating stomach disease and its preparation method and application | |
| CN103919845B (en) | A kind of pharmaceutical composition for improving anoxia endurance and its preparation method and application | |
| CN101711823B (en) | Medicines used to treat asthmatic bronchitis | |
| WO2016197878A1 (en) | Pharmaceutical composition for treatment of menopausal syndrome and preparation method thereof | |
| CN1843418B (en) | Chinese medicine extract for treating gastroenteritis, its preparation method and Chinese medicine composition containing the extract | |
| CN101041000B (en) | A kind of pharmaceutical composition for treating snoring and its preparation method | |
| CN104524359B (en) | A kind of Chinese medicine composition, its preparation method and application | |
| CN102727755A (en) | Traditional Chinese medicine composition for treating gastric ulcer | |
| CN101579386B (en) | Medicinal composition for treating anorexia nervosa | |
| CN109078115A (en) | A kind of Chinese materia medica preparation and preparation method thereof for hemorrhage of digestive tract | |
| CN100998779B (en) | Traditional Chinese medicine granule for relieving exterior syndrome removing dampness and regulating the stomach and its preparing method | |
| CN105748644A (en) | Traditional Chinese medicine composition with effects of stopping cough and relieving asthma and preparation method of traditional Chinese medicine composition | |
| CN100998786B (en) | Traditional Chinese medicine composition granule for treating gastrointestinal disease and its preparing method | |
| CN101757178B (en) | Medicament composition for treating chronic hepatitis and preparation method thereof | |
| CN103127331A (en) | Pharmaceutical composition, and preparation method and application thereof | |
| CN106214910A (en) | A kind of medicine treating dysfunctional uterine bleeding and preparation method thereof | |
| CN102526495A (en) | A kind of medicine for treating stomach disease and preparation method thereof | |
| CN100998784A (en) | Traditional Chinese medicine composition tablet for treating gastrointestinal disease and its preparing method | |
| CN100998803B (en) | Chinese medicinal composition soft capsule for treating gastroantero disease and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150401 |